FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System
This first-of-its-kind technology offers a truly novel approach to treating patients with BTK CLTI disease.
Share
The Spur Stent System is the first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel compliance and reduce vessel recoil effect.
Results of the recently concluded DEEPER REVEAL clinical trial (NCT05358353) to evaluate the Reflow Medical Spur Stent System for below-the-knee (BTK) treatment of chronic limb-threatening ischemia (CLTI), demonstrated that following predilatation, the Spur Stent System achieved a 99.2% technical success 1 rate and 97.0% freedom from MALE 2 and POD 3 at 30 days.
'Clinical data submitted to the FDA demonstrated the safety and efficacy of the Spur Stent System,' said Mahmood K. Razavi, MD, FSIR, FSVM, who serves as Director of the Clinical Trials and Research Center at St. Joseph Heart and Vascular Center in Orange, California. 'This novel device will be a valuable and innovative expansion of our treatment toolbox as a unique device for the treatment of complex BTK disease,' he added.
S. Jay Mathews, MD, MS, FACC, FSCAI, the Cath Lab Director at Bradenton Cardiology/Manatee Memorial Hospital in Bradenton, Florida, commented, 'It's exciting to see the clinical success of the DEEPER REVEAL trial enabling the De Novo clearance of the Spur Stent System. This first-of-its-kind technology offers a truly novel approach to treating patients with BTK CLTI disease. As an adjunct to standard balloon angioplasty, Spur RST enables us to address this complex disease in a more effective way, achieving these outcomes that go beyond what PTA alone can deliver.'
Both Dr. Mathews and Dr. Razavi were lead Principal Investigators for the study, which was conducted at 49 centers in the U.S. and enrolled 130 patients.
'Extensive research and development, which laid the groundwork for the DEEPER REVEAL trial, enabled the creation and clinical validation of the Spur Stent System, an innovative mechanical endovascular device engineered to enhance lesion penetration and optimize the treatment of BTK peripheral arterial disease,' said Teo Jimenez, Senior Vice President of R&D at Reflow Medical.
According to Reflow Medical CEO and Co-Founder, Isa Rizk, 'The FDA's De Novo clearance, following positive clinical trial results in patients with CLTI, enables us to provide physicians with an effective therapeutic option for this growing patient population. We are fully prepared to launch our innovative technology through our dedicated sales force, ensuring it promptly reaches physicians to support patients.'
The FDA decision will be available on their website under DEN240048.
About Reflow Medical, Inc.
Reflow Medical is a global company that partners with leading physicians to develop innovative technologies addressing unmet clinical needs in the endovascular treatment of complex cardiovascular disease. The company's portfolio includes coronary and peripheral microcatheters, crossing catheters, and a revolutionary system known as Retrievable Scaffold Therapy (RST). Products include the CoraCatheters line, available in the U.S. only; the Wingman™, Spex ® and Spex LP, available in the U.S., CE Mark and CE Mark-accepting countries and selected markets; and the Spur ®. Spur received CE Mark approval for the treatment of restenotic lesions in below-the-knee arteries, when used in conjunction with a commercially available drug-coated balloon. Reflow Medical is headquartered in San Clemente, California.
1. Technical success defined as less than 30% residual stenosis by visual estimation; 2. Major adverse limb events; 3. Perioperative death
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Ascensia Launches Global Art Competition Exploring the Link Between Diabetes and Anxiety
BASEL, Switzerland--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, has launched its fourth annual global art competition in support of World Diabetes Day 2025. This year, the competition is themed around Diabetes and Anxiety, shining a spotlight on the mental health impact of diabetes and capturing the unfiltered reality of living with the condition. An estimated 3 in 4 people living with diabetes have experienced anxiety, depression or another mental health condition as a result of managing their diabetes i. With the number of people affected by diabetes expected to rise to over 850 million by 2050 ii, this year's This is Diabetes. This is Anxiety. campaign aims to raise awareness and deepen understanding through creativity and storytelling. Submissions are now open globally and free to enter at until October 24, 2025, with the winners announced on World Diabetes Day, a global initiative of the International Diabetes Federation (IDF), held each year on November 14. Koichiro Sato, CEO of Ascensia Diabetes Care and Chief Operating Officer and Chief Strategy Officer of Ascensia's parent company PHC Group, commented: 'World Diabetes Day is a key moment for us to support the global diabetes community. For 2025, we want to shed light on the emotional burden that often goes unseen. The theme of 'This is Diabetes. This is Anxiety.' is deeply important, and we hope this competition provides an outlet for expression, connection and better quality of life.' 'Each year we are inspired by the stories shared through art,' he continued. 'We invite artists, supporters, and advocates to help us show the world what anxiety and diabetes truly look like. Every submission adds to a collective story that deserves to be seen and heard.' In addition to showcasing the Top 20 submissions across Ascensia's platforms, the 2025 competition will introduce a free downloadable coloring-in booklet featuring selected artwork. This new initiative is designed to spark creativity, reflection and learning for individuals and families alike. Prizes include donations of €6,000, €3,000 and €1,000 made in the winners' names to a diabetes charity of their choice. A diverse judging panel – including global artists, diabetes advocates, and Ascensia employees – will evaluate submissions based on creativity, emotional impact, connection to the theme, and storytelling. Now in its fourth year, the competition builds on the momentum of previous This is Diabetes campaigns, which have drawn over 500 entries and delivered donations to diabetes charities on four continents. Ascensia Diabetes Care is a PHC Holdings Corporation (TSE: 6523) company. Terms and conditions apply. Notes for Editors About Ascensia Diabetes Care Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives. We are home to the world-renowned CONTOUR ® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity. Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: About PHC Holdings Corporation PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service precision technology across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries.
Business Wire
2 hours ago
- Business Wire
vVARDIS' Drill-Free Solution Curodont ™ Has Treated Over One Million Teeth in 18 Months and Is the Fastest Growing Dental Care Product in Its Category
ZUG, Switzerland--(BUSINESS WIRE)-- vVARDIS, a Swiss high-growth healthcare company, active in the development of innovative dental products, today announced that more than one million teeth and more than 420,000 patients have been treated in the United States since January 2024 with Curodont™, its drill-free solution for early stage tooth decay, making it the fastest growing dental care product in its category i ii. Nearly 80 percent of all dental patients have early tooth decay iii. Oral health is an important aspect of overall health, and poor oral health, including untreated decay, can become life-threatening. With Curodont™, dental teams have a drill-free solution to treat tooth decay at an early stage. Curodont™ represents a true win-win proposition: patients benefit from a quick, needle- and drill-free treatment, while dental professionals can treat early decay within minutes—eliminating the need for a follow-up appointment and freeing up chair time for more complex procedures. 'Now that Curodont™ is available in nearly 10 percent of U.S. dental offices iv, an increasing number of dental professionals – or 'Curodontists' – are embracing our treatment and giving patients access to this revolutionary solution,' said Dr. Haley Abivardi, DMD, co-CE, and co-founder of vVARDIS. 'Such high-speed adoption shows how dental professionals have been waiting for decades for a solution that enables them to treat tooth decay at an early stage.' Dr. Goly Abivardi, DMD, co-CEO and co-founder of vVARDIS, said, 'We are thrilled to witness a ground-breaking transformation in dentistry similar to the advancements that medicine embraced years ago toward non-invasive, early intervention approaches. In the same way, Curodont™ is helping to elevate the standard of care for the early treatment of cavities.' With more than 25 years of science, vVARDIS' Curodont™ is backed by universities internationally and has earned the endorsement of renowned thought leaders, clinical experts, and innovators across the dental profession: Dr. German O. Gallucci, Chair of the Department of Restorative Dentistry and Biomaterials Sciences at Harvard School of Dental Medicine, said, 'Curodont™ is highly effective for treatment of early decays. This new non-invasive therapeutic option is a game changer in the battle against tooth decay.' Prof. Amid I. Ismail, Laura H. Carnell Professor and Dean of the Kornberg School of Dentistry, Temple University, said, 'As an epidemiologist and cariologist who has studied dental caries for over four decades and developed guidelines for its diagnosis and management, I can state without hesitation that the advent of Curodont™ represents a significant breakthrough in caries management.' Dr. Timothy Quirt, DDS, MBA, Senior Vice President, Clinical Operations at Heartland Dental, said, 'Curodont™ represents a transformative step forward in dentistry. At Heartland Dental, we've seen firsthand how this innovation empowers clinicians to treat early-stage caries non-invasively, improving outcomes and deepening patient trust. It's not just a product – it's a shift in how we think about the future of oral health.' Dr. Shan K. Bagby, DMD, MHA, FACHE, Brigadier General, USA (Ret.) has recognized Curodont's™ potential to improve the health of children from lower-income homes, saying, 'What makes Curodont™ especially impactful is its potential to reduce tooth decay among vulnerable populations—particularly children and those covered by Medicaid. Curodont™ isn't just a new tool; it's a meaningful, science-driven advancement that is reshaping healthcare and setting a higher standard for dentistry where it's needed most." v Prof. Avijit Banerjee, Professor of Cariology & Operative Dentistry; Hon Consultant in Restorative Dentistry, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, said, 'The scientific research into Curodont™ Repair technology has been well documented in reputable scientific peer-reviewed journals since the late 1990s. Multiple published clinical studies, including systematic meta-analyses, have provided evidence that, unlike conventional topical re-mineralizing agents which primarily act on the surface of the tooth, Curodont™ Repair can treat early decay throughout the depth of the lesion.' vi Prof. Ivo Krejci, University of Geneva, said: 'Curodont™ is no longer the future. It's the present and it should be part of the treatment spectrum in every modern dental practice.' vVARDIS's Curodont™ products are currently available in the U.S. and Europe and will continue to roll out globally. About Curodont™ Using a proprietary biomimetic formulation, Curodont™ is a groundbreaking clinically proven drill-free treatment for early tooth decay. It replicates and builds on the body's natural defenses, working together with minerals in the saliva to repair the damage done to the tooth in the early stages of tooth decay. Curodont™ is a non-invasive, drill-free solution: once the formula is applied, it diffuses through the enamel and repairs the missing parts of the tooth (lesions) with minerals from saliva by mimicking the way nature created teeth (biomimetic). The beauty of this product is that Curodont™ helps patients save the natural tooth structure without artificial filling materials. About vVARDIS AG vVARDIS is a Swiss high-growth healthcare company located in Zug, Switzerland that offers groundbreaking biomimetic, non-invasive solutions for dental professionals under the Curodont™ brand. Founded by Drs. Haley and Goly Abivardi, sisters, Swiss dentists, innovators, and awarded entrepreneurs, vVARDIS is the result of more than 25 years of research, paired with the commitment of its founders to make an impact on people's lives, especially the underserved. vVARDIS' mission is to expand access to novel approaches to the standard of care in dentistry with the purpose of improving oral health – the foundation for overall health. vVARDIS is backed by more than 25 years of science, 230 scientific publications, including meta-analysis, peer-reviewed clinical studies and a long-term peer-reviewed real-world evidence study demonstrating a success rate above 90 percent. It has been used in clinical practice for more than 10 years. Curodont™ is already mentioned in lectures at renowned universities as a standard of care for the treatment of early decay. and
Business Wire
2 hours ago
- Business Wire
SFI Health™ Celebrates Neurodiversity with Inclusive Global Workplace Initiatives
LUGANO, Switzerland--(BUSINESS WIRE)--SFI Health™ is proud to introduce global comprehensive initiatives to celebrate and support neurodiversity within its workforce. As a global company operating across multiple time zones and cultures, SFI Health™ recognizes that embracing diverse ways of thinking is essential to drive innovation, enhance employee wellbeing, and deliver superior value to customers worldwide. 'Research shows that diverse workforces are linked to greater profitability and enhanced wellbeing. By embracing 'thinking differently', we aim to unlock new ideas that serve our customers better and foster a culture where all employees feel valued.' Share Specifically, the 2025 edition of these initiatives, titled ' Every mind matters, Every action helps ', aims to foster a more inclusive, innovative, and supportive work environment for all team members, recognizing the unique strengths and perspectives that neurodiverse and neurotypical individuals bring to the organization. As part of this commitment, the SFI Health EMEA, the regional office of SFI Health™, has arranged a series of programs and resources, which all team members are encouraged to engage with and contribute to further strengthen inclusivity: Webinar ' A Celebration of Neurodiversity at SFI Health: Every Mind Matters, Every Action Helps.' hosted by Dr. Tony Lloyd, an internationally renowned consultant and trainer, specialising in neurodiversity. This educational session, addressed to employees, as well as open to commercial distributors, aims to deepen understanding of neurodiversity, and to help acknowledge the benefits from neuro-inclusion to build a stronger and more connected business community. Specifically, this could mean reshaping recruitment, onboarding and assessment processes by adopting a strength-based approach. Virtual Awareness Session – ' Understanding Neurodiversity: ADHD, Autism & Sensory Sensitivities '. This session provides an overview of ADHD and autism, their overlapping traits, lesser-known metabolic aspects of autism, and their impact on sensory challenges and workplace coping strategies. The event will also feature a personal testimonial from a person diagnosed as autistic after the age of 20, offering insights to promote better understanding, empathy, and support for a more inclusive work environment. Employees Workshop: This collaborative workshop focuses on enhancing internal teamwork among colleagues: employees have been invited to share their thinking style, their approaches to problem-solving and communication, fostering greater mutual understanding and effective collaboration. Following these events, a company-wide survey will be conducted to evaluate learning outcomes and assess employees' confidence in applying neurodiversity principles in their day-to-day work. The insights gathered will inform future initiatives, helping embed neuro-inclusion as a foundational pillar of SFI Health™'s culture. ' Neurodiversity refers to the natural variation in human brains and minds,' said Dr. Tony Lloyd, consultant, psychotherapist, coach & neurodiversity specialist. ' Far from being a limitation, these differences have an evolutionary purpose and represent unique strengths — from creative problem-solving and pattern recognition to hyperfocus and analytical thinking — which can fuel innovation and competitive advantage.' ' Research shows that diverse workforces are linked to greater profitability and enhanced wellbeing,' commented Matthew Brabazon, General Manager at SFI Health™ EMEA. ' At SFI Health ™, this initiative aligns with our core values of promote diversity, respect, empathy, and continuous learning. By embracing 'thinking differently', we aim to unlock new ideas that serve our customers better and foster a culture where all employees feel valued.' About SFI Health ™ SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing. Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions. An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa. SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide. For more information go to or follow us SFI Health on LinkedIn.
